Neuromodulation (ECT, TMS): Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• SessionStimulation and/or Surgical Approaches to Psychiatric Illness

  Cristina Cusin

  Evening seminar on brain stimulation and neurosurgical options for refractory psychiatric illness.

• LectureNeuromodulation and Interventional Psychiatry

  Joan Camprodon

  An overview of TMS, ECT, and other device-based and interventional treatments.

MasterPsych Psychiatry Conference 2026

October 19–22, 2026 · Newport Beach, CA

• LectureTreatment-Resistant Depression (TRD): Advanced Management Strategies

  Adrian Preda

  Advanced pharmacologic and interventional options for depression unresponsive to first-line treatment.

  Ketamine & EsketamineTreatment-Resistant Depression

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• LectureAccelerated Theta Burst Stimulation for Treatment-Resistant Depression in ASD: From Open-Label Promise to Randomized Controlled Trial

  Rana Elmaghraby

  A talk within a symposium on depression in neurodiverse and gender-variant youth, covering accelerated theta burst stimulation for treatment-resistant depression in autistic youth, from open-label findings toward a randomized controlled trial.

  Autism & Neurodevelopmental DisordersChild & AdolescentTreatment-Resistant Depression

• LectureECT in Pediatric Treatment-Resistant Psychosis: Efficacy and Key Challenges

  Shruti Tilak

  Reviews the efficacy of ECT for treatment-resistant psychosis in young patients and the challenges involved.

  Child & AdolescentSchizophrenia & Psychosis

• LectureNeuromodulation for Patients With Autism Spectrum Disorder: Evidence and Clinical Advances in Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS)

  James Luccarelli

  Reviews the evidence and recent clinical advances for ECT and TMS in patients with autism spectrum disorder.

  Autism & Neurodevelopmental Disorders

• SessionGoing From Lorazepam 140 Mg to Zero: A Cross-Country Transfer for Electroconvulsive Therapy

  Aishwarya Rajagopalan · Anastasia Klott · Jacob Feigal · Jonathan R. Komisar · Beau A. Carubia · Alejandra Chavez

  Case conference on severe malignant catatonia from anti-NMDA receptor encephalitis requiring a cross-country transfer for ECT, used to spotlight state-level legal barriers to pediatric ECT access, with the patient and family perspective included.

  CatatoniaChild & AdolescentInflammation & Immunopsychiatry

• LectureThe Use of ECT for Catatonia in Autistic and Nonautistic Patients

  Joshua Ryan Smith

  Looks at ECT use for catatonia, comparing autistic and nonautistic patients.

  Autism & Neurodevelopmental DisordersCatatonia

See all 23 neuromodulation (ect, tms) sessions at this meeting →

APNA 40th Annual Conference

October 28–31, 2026 · Phoenix, AZ

• LectureStrength in Stimulation: Advancing Wellness Through rTMS as an Innovative Treatment for Depression

  Kateleen Collins · Natalie Ramirez · Kenneth Pierce

  Reviews rTMS evidence and shows how multidisciplinary teams can expand neuromodulation access in acute settings.

  Depression

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• SymposiumNeuromodulation to Treat Addictions: What's Available and What's in the Pipeline

  Manish Jha · Kathleen Brady · Hamed Ekhtiari · Gregory Sahlem · Brian Mickey

  Reviews current and investigational neuromodulation techniques for substance use disorders, including rTMS and focused ultrasound.

  Drug Pipeline & Clinical TrialsSubstance Use Disorders

• WorkshopThe Vagus Nerve and Neurostimulation for Opioid Use Disorder and Chronic Pain

  Zev Schuman-Olivier · Alta DeRoo

  Explores vagus nerve stimulation and related neurostimulation approaches for opioid use disorder and chronic pain.

  Opioid Use Disorder

• SymposiumSymposium II - Neuromodulation to Treat Addictions: What’s Available and What’s in the Pipeline

  Manish Jha · Kathleen Brady · Hamed Ekhtiari · Gregory Sahlem · Brian Mickey

  Examines current and emerging neuromodulation approaches such as rTMS and focused ultrasound for treating substance use disorders, including personalization and response monitoring.

  Drug Pipeline & Clinical TrialsSubstance Use Disorders

• PosterThe Effects of Neuromodulation of craving, abstinence, mood, and Neurobiological Outcomes in Cocaine Use disorder: A Meta-Analytic Review

  Manvir Bhangu

  Meta-analysis of neuromodulation effects in cocaine use disorder.

  Substance Use Disorders

NPA 32nd Annual Psychopharmacology Update 2027

February 10–13, 2027 · Las Vegas, NV

• LectureAccelerated Neuromodulation in the Treatment of Depression

  Scott Aaronson

  Accelerated TMS protocols and other rapid-acting neuromodulation strategies for depression.

  Depression

Substance Use Disorders: A Comprehensive Review and Update 2027

February 15–17, 2027 · Lake Buena Vista, FL

• LectureNeurotherapeutics

  Vinod Rao

  Overview of neurotherapeutic approaches relevant to alcohol use disorder and comorbid conditions.

  Alcohol Use Disorder

39th ECNP Congress

October 10–13, 2026 · Munich, Germany

• SymposiumS12 – New Findings Symposium

  A. Coen Coomans · Bengisu Aksoy · Maja Friedemann · Edoardo Pisa · Minh Nguyen · Laura Costantini

  Six short talks on brand-new findings, from personalized rTMS targets in OCD to glymphatic function in depression and transcranial ultrasound stimulation.

  DepressionOCD & Related Disorders

• CourseCS01 - ECNP Neuromodulation Course Session – from mechanisms to clinical application

  Roel Mocking · Iris Dalhuisen · Annemiek Dols · Victoria Stiglbauer

  Interactive course working through difficult-to-treat OCD and depression cases with neuromodulation approaches.

  OCD & Related DisordersTreatment-Resistant Depression

• SymposiumS16 – Cutting edge neuromodulation methods in brain disorders: methods, mechanisms and personalised targeting

  Yvan Vachez · Katya Rubia · Odile van den Heuvel · Christine Reif-Leonhard

  DBS, trigeminal nerve stimulation in ADHD, rTMS-augmented exposure therapy for OCD, and implantable VNS for difficult-to-treat depression.

  ADHDOCD & Related DisordersTreatment-Resistant Depression

• SymposiumS21 – Neurobiology and clinical translation of treatment resistance in major psychiatric disorders

  Michael Ziller · Esmée Verwijk · Alessandra Minelli · Koen Demyttenaere

  iPSC models, pharmacogenomics, ECT cognitive effects, and lived-experience perspectives on treatment resistance.

  Neuroscience & MechanismsPharmacogenomics & Precision PsychiatryTreatment-Resistant Depression

WCP 2026 — 26th World Congress of Psychiatry

September 23–26, 2026 · Stockholm, Sweden

• SymposiumAdvancing Precision Neuromodulation for Treatment-resistant Depression: From Network Biomarkers to Optimized and Novel Shockwave-based and Convulsive Brain Stimulation Therapies

  Treatment-Resistant Depression

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• SymposiumSuicide Prevention in Psychiatric Practice: A Logical, Evidence-Based Framework

  Jill Harkavy-Friedman · Cory Weissman

  Reviews treatments with demonstrated anti-suicidal benefit — lithium, clozapine, ECT, and CBT-based approaches — within a structured framework for individualized prevention planning. Developed with the American Foundation for Suicide Prevention.

  ClozapineLithium & Mood StabilizersSuicide & Self-Harm

• SymposiumNeuromodulation for Depression: Matching the Right Treatment to the Right Patient

  Lisa Harding · Michael Asbach

  Four case scenarios guide selection among TMS, ECT, VNS, theta-burst, and accelerated protocols, comparing mechanisms, indications, and sequencing within overall treatment plans.

  DepressionTreatment-Resistant Depression